29 completed, 10 terminated, 3 active not recruiting, 3 withdrawn. 12 Phase 3, 12 Phase 4, 6 Phase 2, 5 Phase 1.
Follow Tecfidera: new trials by email Literature Review of Tecfidera trials Research Report on Tecfidera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) Diroximel Fumarate, Dimethyl Fumarate, Fingolimod - Relapsing Forms of Multiple Sclerosis | Phase 3 | Not yet recruiting | Biogen | 185 | 2026-11-16 | 2026-03-19 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) Diroximel Fumarate, Dimethyl Fumarate, Disease-Modifying Therapies (DMTs) - Multiple Sclerosis | Active not recruiting | Biogen | 10500 | 2024-06-08 | 2026-10-26 | |
| Dimethyl Fumarate in Adrenomyeloneuropathy Placebo, Dimethyl fumarate - Adrenomyeloneuropathy Without Cerebral Involvement | Phase 2 / Phase 3 | Active not recruiting | Pujol, Aurora, M.D. | 40 | 2024-04-23 | 2026-06-17 |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) Diroximel Fumarate, Avonex, Tysabri - Multiple Sclerosis | Recruiting | Biogen | 908 | 2023-10-27 | 2026-08-11 | |
| A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China Dimethyl fumarate - Multiple Sclerosis | Phase 4 | Completed | Biogen | 60 | 2023-06-09 | 2025-05-16 |
| Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) Vumerity, Tecfidera - Multiple Sclerosis (MS) Relapsing Remitting | Active not recruiting | University of Colorado, Denver | 11 | 2023-03-07 | 2026-08-11 | |
| Relationship Between Oral DMT Burden and Adherence in MS Cladribine, Dimethyl fumarate, Fingolimod - Multiple Sclerosis, Adherence, Medication | Unknown | Monash University | 323 | 2020-09-25 | 2022-08-31 | |
| Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers Bafiertam, Tecfidera - Multiple Sclerosis | Phase 1 | Completed | Banner Life Sciences LLC | 210 | 2019-07-07 | 2020-01-18 |
| Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants Dimethyl Fumarate, Peginterferon Beta-1a, Placebo - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Biogen | 11 | 2019-03-19 | 2023-06-15 |
| Teriflunomide Tecfidera LMCE Dimethyl Fumarate, Teriflunomide - Tecfidera, Teriflunomide | Completed | University at Buffalo | 120 | 2018-06-14 | 2021-01-06 | |
| A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 ALKS 8700, Dimethyl Fumarate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Completed | Biogen | 506 | 2017-03-15 | 2020-07-14 |
| A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis Evobrutinib, Placebo, Tecfidera - Relapsing-remitting Multiple Sclerosis | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 267 | 2017-03-07 | 2025-05-14 |
| Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects monomethyl fumarate 190 mg, dimethyl fumarate 240 mg - Relapsing Remitting Multiple Sclerosis | Phase 1 | Completed | Banner Life Sciences LLC | 50 | 2017-01-06 | 2022-12-30 |
| Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis Dimethyl fumarate, Placebo - Primary Progressive Multiple Sclerosis | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 54 | 2016-12-01 | 2020-12-24 |
| Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Dimethyl Fumarate (DMF), Placebo Oral Tablet - Systemic Sclerosis, Pulmonary; Hypertension | Phase 1 | Terminated | Robert Lafyatis | 6 | 2016-12-01 | 2022-03-17 |
| Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece Dimethyl Fumarate (DMF) - RRMS | Completed | Genesis Pharma CNS & Specialty | 455 | 2016-09-23 | 2021-07-28 | |
| Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL dimethyl fumarate - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Terminated | Michael Choi | 2 | 2016-06-01 | 2019-09-19 |
| RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. Rituximab, Dimethyl fumarate, Sodium Chloride solution - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Anders Svenningsson | 200 | 2016-05-01 | 2021-10-12 |
| Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS Dimethyl Fumarate - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Withdrawn | Washington University School of Medicine | 2016-04-01 | 2016-07-20 | |
| Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Tecfidera, Placebo - Multiple Sclerosis (MS) | Phase 4 | Completed | University of Texas Southwestern Medical Center | 87 | 2016-03-19 | 2022-05-11 |
Showing 20 of 49. Sign in to see all of them.
Multiple Sclerosis (24) · Multiple Sclerosis, Relapsing-Remitting (22) · Multiple Sclerosis, Chronic Progressive (2) · Recurrence (2) · Flushing (1) · Hypertension, Pulmonary (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Medication Adherence (1) · Neoplasms (1) · Scleroderma, Diffuse (1) · Scleroderma, Systemic (1) · Sleep Apnea Syndromes (1) · Sleep Apnea, Obstructive (1) · Snoring (1)
Biogen (30) · Banner Life Sciences LLC (2) · Anders Svenningsson (1) · Copenhagen University Hospital, Rigshospitalet (1) · EMD Serono Research & Development Institute, Inc. (1) · Genesis Pharma CNS & Specialty (1) · IMS HEALTH GmbH & Co. OHG (1) · Michael Choi (1) · Monash University (1) · Oregon Health and Science University (1) · Pujol, Aurora, M.D. (1) · Robert Lafyatis (1) · University at Buffalo (1) · University of Colorado, Denver (1) · University of Michigan (1)
United States (30) · Poland (9) · Czechia (8) · Spain (8) · Canada (7) · Germany (7) · Italy (7) · United Kingdom (7) · Belgium (6) · Australia (5) · France (5) · Ireland (5) · Slovakia (5) · Bulgaria (4) · Hungary (4)
Anders Svenningsson, MD, PhD (1) · Anne Cross, MD (1) · Carlos Casasnovas, MD, PhD (1) · Daniel Pelletier, MD (1) · Darin T Okuda, MD (1) · Enrique Alvarez, MD/PhD (1) · Ernest Butler, PhD; MD (1) · Franck Rousseau, MD (1) · Jacob Lando Talbot, MD (1) · Kathleen Doisy, MD (1) · Laura Piccio, MD (1) · Michael Choi, MD (1) · Rebecca Spain, MD, MSPH (1)
PMID 39570545, PMID 19073949, PMID 26932146, PMID 29159204, PMID 29524759, PMID 29800466, PMID 30206820, PMID 30470580, PMID 30616596, PMID 30870983, PMID 30918100, PMID 31075187, PMID 31391949, PMID 31832225, PMID 31953790, PMID 32426039, PMID 33225410, PMID 33796143, PMID 33797063, PMID 34429340, PMID 34815321, PMID 35841908, PMID 36126241, PMID 36169959, PMID 36401339, PMID 36418156, PMID 37061656, PMID 37345645, PMID 37354276, PMID 37369602, PMID 37626477, PMID 37651844, PMID 38335474, PMID 38878121, PMID 39673658, PMID 41390331
2014 (2), 2015 (2), 2008 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1)